中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (11): 823-826.doi: 10.12144/zgmfskin202511823

• 病例报告 • 上一篇    下一篇

托法替布治疗幼年型毛发红糠疹一例

陈晓萱1，2,刘永霞1，2,李珍1，2,田洪青1，2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2025-11-15 发布日期:2025-11-11

Juvenile pityriasis rubra pilaris successfully treated with tofacitinib: a case report

CHEN Xiaoxuan1,2, LIU Yongxia1,2, LI Zhen1,2, TIAN Hongqing1,2   

  1. 1 Dermatology Hospital of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2025-11-15 Published:2025-11-11

PDF (PC)

15

摘要： 对于儿童毛发红糠疹患者，轻症患者多外用药物局部治疗，对于病情较重或局部治疗效果不佳的患者，可应用维A酸类药物及甲氨蝶呤等免疫抑制剂，但不良反应较多，且尚未有确切的治疗有效率统计。近年来有文献报道生物制剂和小分子药物治疗安全有效的案例，本文报道一例复发性幼年型毛发红糠疹男性患者，在应用托法替布治疗1个月后，皮疹基本消退，随访3年未复发。

关键词: 托法替布, 毛发红糠疹, 幼年型

Abstract: For pediatric patients with pityriasis rubra pilaris (PRP), mild cases are often treated topically with external medications. For patients with more severe conditions or inadequate response to local therapy, systemic treatments such as retinoids and immunosuppressants like methotrexate may be administered. However, these options are associated with numerous adverse effects, and no definitive treatment efficacy rates have been established. In recent years, there have been reports of biologics and small molecule drugs demonstrating both safety and effectiveness in treating PRP. This article presents a case of a male patient with recurrent juvenile PRP who achieved near-complete resolution of skin lesions after one month of tofacitinib treatment and remained recurrence-free during a three-year follow-up period.

Key words: tofacitinib, pityriasis rubra pilaris, juvenile